Ana Cristina Andreazza: Driven by curiosity – transforming mental health through mitochondrial innovation

Dr. Ana Cristina Andreazza is a Professor of Pharmacology Toxicology and Psychiatry at the University of Toronto, holding the Thomas C. Zachos Chair in Mitochondrial Research and a Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders. As the visionary Founder and Scientific Director of the Mitochondrial Innovation Initiative (Mito2i), she leads pioneering research on the role of mitochondrial dysfunction in neurological and psychiatric diseases, organ transplants, and novel therapeutic strategies. Her groundbreaking work has revolutionized our understanding of the relationship between mitochondrial function and mental health disorders, particularly bipolar disorder. Dr. Andreazza's career was inspired by early curiosity, family influence, and a commitment to reduce the stigma surrounding metabolic and psychiatric conditions. Her innovative work bridges multiple disciplines, aiming to discover biomarkers that could enable personalized treatments in mental health. A recipient of numerous prestigious awards, including membership in the Royal Society of Canada College of New Scholars, Dr. Andreazza has published over 200 peer-reviewed papers and is internationally recognized for her contributions to metabolic psychiatry. In this Genomic Press Interview, she shares insights into her remarkable journey from studying wine chemistry in Brazil to becoming a leading force in mitochondrial research while discussing her perspectives on collaborative science and innovation. Driven by a passion for teaching and collaborative science, Dr. Andreazza continues to foster innovation and mentorship in the mitochondrial research community.